Matthias Holdhoff, M.D., Ph.D.

Headshot of Matthias Holdhoff
  • Co-Director, Brain Cancer Disease Group, Sidney Kimmel Comprehensive Cancer Center
  • Associate Professor of Oncology

Languages: English, German


Brain Cancer, Brain Tumors, Medical Oncology, Neuro-Oncology, Primary Central Nervous System (CNS) lymphoma more

Research Interests

Clinical Trials in Primary Brain Cancers; Translational Research in Neuro-Oncology more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment


Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-955-8964


Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is an associate professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas.

He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab).

As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations.

Dr. Holdhoff is director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. In addition, he is co-director of the combined Johns Hopkins University/National Institutes of Health neuro-oncology fellowship program, and he is a teaching attending physician for the Osler internal medicine residency program. more


  • Co-Director, Brain Cancer Disease Group, Sidney Kimmel Comprehensive Cancer Center
  • Associate Professor of Oncology
  • Associate Professor of Neurology
  • Associate Professor of Neurosurgery
  • Joint Appointment in Medicine

Departments / Divisions

Centers & Institutes



  • MD; Freie Universitat Berlin (2003)


  • Internal Medicine; Johns Hopkins Bayview Medical Center (2007)


  • Oncology; Johns Hopkins University School of Medicine (2010)

Board Certifications

  • American Board of Internal Medicine (Internal Medicine) (2007)
  • American Board of Internal Medicine (Oncology) (2009)

Additional Training

  • Maryland Medical License
  • District of Columbia Medical License

Research & Publications

Research Summary

Dr. Holdhoff's research is focused on translational research projects and clinical trials in neuro-oncology. His clinical research is concentrated on early phase therapeutic clinical trials in malignant gliomas, including glioblastomas, as well as in primary central nervous system lymphomas. He is leading or participating in multiple brain cancer trials, including within the Adult Brain Tumor Consortium. In addition, he is working on novel biomarkers to assess response and disease activity, including liquid biopsy approaches, in malignant gliomas and primary central nervous system lymphomas.

Selected Publications

View all on PubMed

Holdhoff M, Ye X, Piotrowski AF, Strowd RE, Seopaul S, Lu Y, Barker NJ, Sivakumar A, Rodriguez FJ, Grossman SA, Burger PC. The consistency of neuropathological diagnoses in patients undergoing surgery for suspected recurrence of glioblastoma. J Neurooncol. 2019 Jan;141(2):347-354. doi: 10.1007/s11060-018-03037-3. Epub 2018 Nov 9. PMID: 30414096; PMCID: PMC6342857.

Schreck KC, Ranjan S, Skorupan N, Bettegowda C, Eberhart CG, Ames HM, Holdhoff M. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol. 2019

Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, Leal J, Fisher JD, Desideri S, Grossman SA, Wahl RL, Schiff D. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro Oncol. 2017 Jun 1;19(6):845-852. doi: 10.1093/neuonc/nox020. PMID: 28371832; PMCID: PMC5464434.

Holdhoff M, Guner G, Rodriguez FJ, Hicks JL, Zheng Q, Forman MS, Ye X, Grossman SA, Meeker AK, Heaphy CM, Eberhart CG, De Marzo AM, Arav-Boger R. Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ Hybridization. Clin Cancer Res. 2017 Jun 15;23(12):3150-3157. doi: 10.1158/1078-0432.CCR-16-1490. Epub 2016 Dec 29. PMID: 28034905; PMCID: PMC5474132.

Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, Grossman SA, Ye X. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014 Jul 15;83(3):235-9. PMID:24928128

Activities & Honors


  • Member, Miller Coulson Academy of Clinical Excellence
  • Leadership Development Program, ASCO
  • Director’s Teaching Award in Clinical Science, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Merit Award, Conquer Cancer Foundation
  • Young Investigator Award, Conquer Cancer Foundation
  • Best Bedside Manner Award, Johns Hopkins Bayview Medical Center
  • Alumnus, German Academic Scholarship Foundation (Studienstiftung des deutschen Volkes)

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Is this you? Edit Profile
back to top button